logo
Premise Health Honored as a 5 Star Employer by VETS Indexes

Premise Health Honored as a 5 Star Employer by VETS Indexes

Yahoo06-05-2025
BRENTWOOD, Tenn., May 6, 2025 /PRNewswire/ -- Premise Health has been recognized as a 5 Star Employer by the VETS Indexes Employer Awards for its strong commitment to recruiting, hiring, retaining, developing, and supporting veterans and the military-connected community. The "5 Star Employer" distinction is the highest one possible in the Employer Awards.
Premise Health, the leading direct healthcare provider for employers and unions, formalized its military program for veterans, military spouses, National Guard and Reservists in 2016. The program previously received VETS Indexes' 3 and 4 Star designations in 2023 and 2024 respectively. The new 5 Star recognition is the direct result of the organization's alignment to support its military-connected community according to its mission of helping people get, stay, and be well.
"This recognition by VETS Indexes represents an organization-wide effort to ensure that Premise is a place where the military community is respected, understood and truly valued," said Premise's Military Program Manager Matt Watkins.
"We're honored to receive this designation. It's a reflection of the commitment, care and hard work that Premise team members demonstrate daily, whether it's in support of veterans, military spouses or the broader military-connected community."
Recipients of the Employer Award were announced during this year's Employing U.S. Vets Conference on April 10. VETS Indexes, a national leader in veteran employer evaluation, reported a record application year with Premise joining a select group of organizations to receive this distinction. Applicants included large and small employers, government agencies and departments, nonprofit groups, and institutions of higher education.
The VETS Indexes Employer Awards program is the most objective and comprehensive evaluation of veteran employers. This in-depth survey and recognition program analyzes employers' policies, practices, and outcomes regarding the recruitment, hiring, development, retention, and support of military-connected team members.
Premise and its military program provide dedicated resources for military-connected team members and applicants, including an ombudsman program, flexible work options, team member resource groups, mentorship programs, and extensive internal support from top-level executives to frontline leaders.
Externally, Premise partners with veteran-focused organizations across the nation in its effort to support the career advancement of veterans and their families, such as Hiring Our Heroes, Military Spouse Employment Partners, the Charlie and Hazel Daniels Veterans and Military Family Center at Middle Tennessee State University, and INvets (Indiana).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time18 minutes ago

  • Yahoo

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio

CONMED (CNMD) Q2 Earnings: What To Expect
CONMED (CNMD) Q2 Earnings: What To Expect

Yahoo

time18 minutes ago

  • Yahoo

CONMED (CNMD) Q2 Earnings: What To Expect

Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time18 minutes ago

  • Yahoo

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store